Patents Issued in December 31, 2020
-
Publication number: 20200407377Abstract: The present invention relates to a process for the preparation of crisaborole of formula (I): by preparing intermediates of formulas (II) and (III):Type: ApplicationFiled: July 10, 2020Publication date: December 31, 2020Inventors: Federico GASSA, Lazzaro FELICIANI, Alberto MAZZA, Marco QUARONI, Mara SADA, Giorgio BERTOLINI
-
Publication number: 20200407378Abstract: The present invention relates to a perfluoropolyether group-containing silane compound represented by formula (1): Rf—X1—X2—NQkT2-k, (1), and a method for preparing the same. The present invention also relates to a perfluoropolyether group-containing silane compound represented by formula (2), and a method for preparing the same. The present invention also relates to a perfluoropolyether group-containing silane compound represented by formula (3), and a method for preparing the same. The perfluoropolyether group-containing silane compound of the present invention can be used for a surface treatment agent so that the substrates such as glass etc processed by the surface treatment agent are excellent in anti-fouling, anti-fingerprint, scrape resistant and abrasion resistant performances. Moreover, the preparation method of each of the compounds of the present invention is simple in process, easy to operate and implement.Type: ApplicationFiled: September 11, 2020Publication date: December 31, 2020Inventors: Yijing CHEN, Qiguan WANG
-
Publication number: 20200407379Abstract: Provided is a method for producing a cyclic polysilane compound from a silane monomer compound in one-pot approach. The method for producing a cyclic polysilane compound according to an embodiment of the present invention includes a first step of adding and reacting a silane monomer compound in a liquid mixture of a sodium dispersion and a solvent; and a second step of adding an aromatic hydrocarbon to a reaction solution of the first step and heating and refluxing.Type: ApplicationFiled: March 7, 2019Publication date: December 31, 2020Applicant: Kureha CorporationInventors: Ryota NAITO, Hiraku TOHMIYA
-
Publication number: 20200407380Abstract: According to the organometallic compound of the present invention and the thin film manufactured using the same, requirements of high volatility and excellent chemical/thermal stability are satisfied, and significantly improved thin-film deposition rates are exhibited even at low temperatures. In addition, property degradation due to by-products can be improved, excellent step coverage can be realized, and a thin film which, due to having a high dielectric constant, electrically satisfies the equivalent oxide thickness (EOT) requirement while having a thickness at which tunneling does not physically occur can be implemented.Type: ApplicationFiled: January 25, 2019Publication date: December 31, 2020Applicant: Mecaro Co., Ltd.Inventors: Seung Won HA, Young Hun BYUN, Jeum Jong KIM, Ho Hoon KIM, Seong Hak CHEON
-
Publication number: 20200407381Abstract: In the field of organic phosphorus chemistry, especially the chemistry of bulky organophosphorus compounds, a process for the synthesis of compound of formula (I). This process is especially useful to obtain chiral bulky phosphorus compounds. The present invention also relates to compounds of formula (VII), (VIII), (IX) and (X) and their processes of manufacturing starting from a compound of formula (I).Type: ApplicationFiled: March 20, 2019Publication date: December 31, 2020Applicant: UNIVERSITÉ DE BOURGOGNEInventors: Jérôme BAYARDON, Antonin JAILLET, Sylvain JUGÉ
-
Publication number: 20200407382Abstract: The present invention discloses novel crystalline polymorphic forms of (9-[(R)-2-[[(S)-[[(S)-1-(isopropoxy carbonyl) ethyl] amino] phenoxyphosphinyl] methoxy]propyl] adenine hemifumarate and 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl] amino]phenoxy phosphinyl]methoxy]propyl] adenine monofumarate, methods of preparation, pharmaceutical compositions and methods of therapeutic treatment involving polymorphic forms thereof.Type: ApplicationFiled: December 28, 2018Publication date: December 31, 2020Inventors: Dharmaraj Ramachandra RAO, Geena MALHOTRA, Srinivas Laxminarayan PATHI, Manjinder Singh PHULL, Ramanaiah CHENNURU
-
Publication number: 20200407383Abstract: The present disclosure relates to the field of organic electroluminescence, in particular to a compound, an organic electroluminescence device and a display device. The compound has a structure shown in a formula (I): and X is selected from O atom or S atom; X1-X8 are each independently selected from C atoms or N atoms, and at least one of X1-X8 is N atoms; A and B are each independently selected from any one or more of the substituted or unsubstituted C6-C40 aryl, and substituted or unsubstituted C4-C40 heteroaryl; R1 is selected from C1-C9 alkyl, substituted or unsubstituted C6-C18 aryl, substituted or unsubstituted C4-C30 heteroaryl.Type: ApplicationFiled: October 3, 2019Publication date: December 31, 2020Applicant: Shanghai Tianma AM-OLED Co., Ltd.Inventors: Wenpeng DAI, Wei Gao, Lei Zhang, Jinghua Niu, Ying Liu, Ping An
-
Publication number: 20200407384Abstract: A compound of Chemical Formula 1, and an organic photoelectric device, an image sensor, and an electronic device including the same are disclosed: In Chemical Formula 1, the definition of each substituent is as described in the detailed description.Type: ApplicationFiled: June 24, 2020Publication date: December 31, 2020Applicant: Samsung Electronics Co., Ltd.Inventors: Chul BAIK, Taejin CHOI, Ji Soo SHIN, Sung Young YUN, Kyung Bae PARK, Gae Hwang LEE, Yeong Suk CHOI, Chul Joon HEO
-
Publication number: 20200407385Abstract: A process is provided for the production of bis-choline tetrathiomolybdate, the process comprising reacting a choline salt with ammonium tetrathiomolybdate, wherein the choline salt is a hydroxide, acetate, or halide choline salt, wherein the process comprises: combining the choline salt with a first mixture of ammonium tetrathiomolybdate in water, wherein a molar excess of choline salt to ammonium tetrathiomolybdate is used, for a first reaction period to provide a first reaction mixture; subjecting the first reaction mixture to a reduced pressure for a second reaction period to provide a second reaction mixture; and, isolating bis-choline tetrathiomolybdate from the second reaction mixture, wherein isolating bis-choline tetrathiomolybdate comprises adding ethanol to the second reaction mixture.Type: ApplicationFiled: February 15, 2019Publication date: December 31, 2020Inventors: Johan Anders WENNERBERG, Hans Roger Marcus MÅRTENSSON
-
Publication number: 20200407386Abstract: A composition which is useful for producing a light emitting device having excellent luminance life contains a compound represented by formula (C-1), a metal complex represented by formula (1) and a metal complex represented by formula (2): Ring R1 C to Ring R4 C represent an aromatic hydrocarbon ring and RC represents a carbon atom. M1 represents an iridium atom, n1 and n2 are integers, Ring R1 A represents a diazole ring, Ring R2 represents an aromatic hydrocarbon ring, E1, E2 and E1 1 A to E1 3 A represent a nitrogen or carbon atom, R1 1 A to R1 3 A represent a hydrogen atom, an alkyl group, or an aryl group, and A1-G1-A2 represents an anionic bidentate ligand. M2 represents an iridium atom, n3 and n4 are integers, EL represents a carbon atom, Ring L1 represents a 6-membered aromatic hetero ring, Ring L2 represents an aromatic hydrocarbon ring, and A3-G2-A4 represents an anionic bidentate ligand.Type: ApplicationFiled: April 20, 2018Publication date: December 31, 2020Inventors: Motoaki USUI, Toshiaki SASADA
-
Publication number: 20200407387Abstract: The present disclosure relates to a process for preparing a transition metal-Schiff base imine ligand complex. The process involves direct chelation of a Schiff base imine ligand by adding a transition metal halide in a halogenated fluid medium at a temperature in the range of 20° C. to 40° C. The process employs less hazardous reagents and mild reaction conditions to obtain the complex. The complex is efficient to be used as a catalyst for the production of disentangled ultra-high molecular weight polyethylene.Type: ApplicationFiled: January 25, 2017Publication date: December 31, 2020Applicants: Reliance Industries Limited, Reliance Industries LimitedInventors: Mahuya Bagui, Yogesh Popatrao Patil, Viralkumar Patel, Raksh Vir Jasra, Ajit Behari Mathur, Gopal Tembe, Uma Sankar Satpathy, Satya Srinivasa Gandham
-
Publication number: 20200407388Abstract: Disclosed is a lignin that is soluble in a medium having a pH greater than or equal to 4, a solution containing same, a method for producing same, and uses thereof, in particular for preparing lignin fibers and carbon fibers. Soluble lignin may be obtained by enzymatic modification.Type: ApplicationFiled: October 16, 2018Publication date: December 31, 2020Inventors: Nicolas MANO, Sébastien GOUNEL, Wilfrid NERI, Alain DERRE, Philippe POULIN
-
Publication number: 20200407389Abstract: The present invention relates to a method for preparing a crystalline functional sweetener, and more specifically, relates to a method for preparing a crystalline functional sweetener for raising the crystallization yield and increasing the particle size by controlling the content of impurities or production of impurities comprised in a solution for preparing the crystal.Type: ApplicationFiled: February 7, 2019Publication date: December 31, 2020Inventors: Go-Eun KIM, Jae-Kyung YANG, Kyung-Hun RYU, Sung Won PARK, Ji Won PARK, Eunsoo CHOI
-
Publication number: 20200407390Abstract: The present invention relates to mannoside derivative compounds useful as inhibitors of FimH and methods for the treatment or prevention of urinary tract infection.Type: ApplicationFiled: July 10, 2020Publication date: December 31, 2020Inventors: James W. JANETKA, Laurel MYDOCK-MCGRANE
-
Publication number: 20200407391Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.Type: ApplicationFiled: September 11, 2020Publication date: December 31, 2020Applicant: Galecto Biotech ABInventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
-
Publication number: 20200407392Abstract: The invention comprises LNA-dicarboxylic acid derivatives of the formula I or salts thereof, wherein R1 is a nucleobase or a modified nucleobase R2 is a hydroxy protecting group and n is an integer from 1 to 5. The LNA-dicarboxylic acid derivatives of the formula I can be used in preloaded solid supports of the formula III and as that serve as suitable start material for oligonucleotide synthesis.Type: ApplicationFiled: September 10, 2020Publication date: December 31, 2020Applicant: Hoffmann-La Roche Inc.Inventors: KURT PUENTENER, CHRISTOPH ROSENBOHM, FILIPPO SLADOJEVICH
-
Publication number: 20200407393Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.Type: ApplicationFiled: March 6, 2019Publication date: December 31, 2020Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED, VIIV HEALTHCARE COMPANYInventors: Martha Alicia DE LA ROSA, John Franklin MILLER, David TEMELKOFF, Emile Johann VELTHUISEN
-
Publication number: 20200407394Abstract: The present invention establishes a molecular therapy for glycogen storage disease type Ia. The present invention provides an oligonucleotide of 15-30 bases comprising a nucleotide sequence complementary to the cDNA of G6PC gene with c.648G>T mutation, wherein the oligonucleotide comprises a sequence complementary to a region comprising any site between the 82nd to the 92nd nucleotide from the 5? end of exon 5 of the G6PC gene with c.648G>T mutation, a pharmacologically acceptable salt or solvate thereof. Also provided is a pharmaceutical drug comprising the oligonucleotide, a pharmacologically acceptable salt or solvate thereof (e.g., therapeutic drug for glycogen storage disease type Ia).Type: ApplicationFiled: March 5, 2019Publication date: December 31, 2020Applicants: DAIICHI SANKYO COMPANY, LIMITED, KOBE GAKUIN EDUCATIONAL FOUNDATIONInventors: Makoto KOIZUMI, Yoshiyuki ONISHI, Takeshi MASUDA, Mitsuhiro IWAMOTO, Yukiko SEKIGUCHI, Kentaro ITO, Shinnosuke TSUJI, Masafumi MATSUO
-
Publication number: 20200407395Abstract: The present disclosure provides certain chiral peptide agents, and uses relating thereto.Type: ApplicationFiled: September 3, 2020Publication date: December 31, 2020Inventor: Andrew D. Levin
-
Publication number: 20200407396Abstract: The disclosure provides methods of preventing, ameliorating or treating disruption of mitochondrial function and symptoms thereof. The methods provide administering aromatic-cationic peptides in effective amounts to prevent, treat or ameliorate the disruption of mitochondrial oxidative phosphorylation in a cell such as that found in a subject suffering from, or predisposed to a mitochondrial disease or disorder. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for a mitochondrial disease or disorder, an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: ApplicationFiled: July 15, 2020Publication date: December 31, 2020Applicant: Stealth BioTherapeutics CorpInventor: D. Travis Wilson
-
Publication number: 20200407397Abstract: The present disclosure is directed to one or more engineered peptide inhibitors against the lactate dehydrogenase A (LDHA) activity in cells. The disclosure also provides compositions, and kits including the one or more peptide inhibitors, and methods of using the one or more peptide inhibitors. The peptide inhibitors and compositions can be used for treatment of conditions in which there is abnormally high LDHA activity, such as cancer or metabolic diseases, infectious diseases, mendelian disorders, inflammatory diseases, neurodegenerative and neuropathological diseases, neuropsychological disorders, obesity and eating disorders, chronic diseases and genetic diseases.Type: ApplicationFiled: June 29, 2020Publication date: December 31, 2020Inventors: Mehdi Mollapour, Gennady Bratslavsky, Mark R. Woodford, Dimitra Bourboulia
-
Publication number: 20200407398Abstract: We evaluated the antibacterial activity of synthetic short proline-rich lipopeptides (SPRLPs) against clinically-relevant Gram-positive and Gram-negative pathogens. The short peptide sequence of SPRLPs were inspired by the repeating PXP motif apparent in longer PRAMPs. We assessed the potential of these SPRLPs to serve as adjuvants in combination with clinically-used antibiotics against P. aeruginosa. Our results revealed an amphiphilic non-hemolytic non-cytotoxic L-lipopeptide lead sequence that strongly potentiates minocycline and rifampicin against MDR/XDR P. aeruginosa. Furthermore, the adjuvant potency is retained in its enantiomeric D-SPRLP counterpart.Type: ApplicationFiled: March 8, 2019Publication date: December 31, 2020Inventors: Frank Schweizer, Ronald Domalaon
-
Publication number: 20200407399Abstract: Novel peptide analogs of a ?-defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response. These novel ?-defensin analogs are protective at concentrations where naturally occurring ?-defensins have no apparent effect, and include a core set of structural and sequence features not found in native ?-defensins.Type: ApplicationFiled: June 26, 2020Publication date: December 31, 2020Inventors: Michael E. Selsted, Dat Q. Tran, Justin B. Schaal, Virginia Basso
-
Publication number: 20200407400Abstract: Novel peptide analogs of a ?-defensin have been developed that provide a biphasic effect in treating infection and/or sepsis. These analogs are active at concentrations below those needed to provide a bactericidal or bacteriostatic effect, and function by initially recruiting effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response characteristic of sepsis and septic shock. These novel ?-defensin analogs are protective at concentrations where naturally occurring ?-defensins have no apparent effect, and include a core set of structural and sequence features not found in native ?-defensin.Type: ApplicationFiled: June 26, 2020Publication date: December 31, 2020Inventors: Michael E. Selsted, Dat Q. Tran, Justin B. Schaal
-
Publication number: 20200407401Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods of treating arthritogenic alphavirus infection and methods of screening.Type: ApplicationFiled: January 4, 2019Publication date: December 31, 2020Applicant: Washington UniversityInventors: Michael DIAMOND, Daved FREMONT, Rong ZHANG, Arthur KIM, Larissa THACKRAY, Katherine BASORE, Christopher A. NELSON
-
Publication number: 20200407402Abstract: The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.Type: ApplicationFiled: September 14, 2020Publication date: December 31, 2020Inventors: Linling He, Jiang Zhu, Ian A. Wilson
-
Publication number: 20200407403Abstract: Disclosed are hypersensitive-response eliciting peptides and non-hypersensitive response eliciting peptides that induce active plant responses, and that exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.Type: ApplicationFiled: September 14, 2020Publication date: December 31, 2020Inventors: Zhongmin WEI, Gregory A. ZORNETZER
-
Publication number: 20200407404Abstract: The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.Type: ApplicationFiled: February 10, 2020Publication date: December 31, 2020Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Richard Malley, Yingjie Lu, Fan Zhang
-
Publication number: 20200407405Abstract: As disclosed herein, the assistance of a new generation of immunotoxins (split-immunotoxins) the range of cancers susceptible to elimination by oncolytic viruses and the specific toxicity of the latter can be expanded without compromising the selectivity of targeting. To accomplish this goal, a polypeptide chain of a potent bacterial toxin (including, but not limited to a catalytic subunit of a Diphtheria toxin, DTA) can be split into two benign parts, which can then be delivered to the cytoplasm of cancer cells via two independent cancer-specific pathways: (1) together with an oncolytic virus (encoded in its genome); (2) as a split-immunotoxin delivered via receptor-specific toxin entry pathways. The two parts are fused into a functional toxin only in the cytoplasm of dually targeted cancer cells by means of intein-catalyzed trans-splicing.Type: ApplicationFiled: February 26, 2019Publication date: December 31, 2020Inventors: Dmitri Kudryashov, Elena Kudryashova, Vedud Purde, Timothy Cripe
-
Publication number: 20200407406Abstract: The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.Type: ApplicationFiled: September 14, 2020Publication date: December 31, 2020Inventors: Luc VANDER ELST, Vincent CARLIER, Jean-Marie SAINT-REMY
-
Publication number: 20200407407Abstract: The present invention relates to an orally-administered gene carrier, and more specifically, to an orally-administered gene carrier having cationic protamine connected to an immunoglobulin Fc region by an SMCC linker, the cationic protamine enabling the condensation of an anionic gene. The orally-administered gene carrier enables protamine, which is a protein having cationic properties, to bind to an Fc region and be condensed with a gene having anionic properties, and thus may effectively induce the in vivo expression of the gene, and when orally administered, may enable the gene to be transferred to the small intestine by protecting the gene from a degradation reaction resulting from an immune action of white blood cells and stomach acid, and may enable the half-life of the gene to be relatively long when the gene is expressed in the small intestine, and thus a potential for a long-term treatment effect has been confirmed.Type: ApplicationFiled: December 21, 2018Publication date: December 31, 2020Inventors: Yong Kyu LEE, Seung Bin CHA, Sung Hun KANG, Sun Hwa LEE
-
Publication number: 20200407408Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.Type: ApplicationFiled: March 7, 2019Publication date: December 31, 2020Applicants: The University of Tokyo, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji MATSUSHIMA, Satoshi UEHA, Shungo DESHIMARU, Chang-Yu CHEN, Shoji YOKOCHI, Yoshiro ISHIWATA, Shiro SHIBAYAMA
-
Publication number: 20200407409Abstract: The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.Type: ApplicationFiled: September 17, 2020Publication date: December 31, 2020Inventors: Jianhe Chen, Jesper F. Lau, Janos Tibor Kodra, Birgit Wieczorek, Lars Linderoth, Henning Thoegersen, Salka Elboel Rasmussen, Patrick William Garibay
-
Publication number: 20200407410Abstract: A peptide is described herein that has: (i) a simple structure compared to existing natural human erythropoietin, thus capable of easily passing through a tissue-blood barrier, (ii) excellent bioactivity with respect to cell-protecting activity, (iii) a low manufacturing cost, thus being economically advantageous, and (iv) no side effects on cell proliferation. Also, a pharmaceutical composition comprising the erythropoietin-derived peptide described herein as an active ingredient is described. The pharmaceutical composition may be used for preventing or treating cell damage-related illnesses, such as stroke, mechanical damage or ischemic damage to the nervous system, myocardial infarction, retinal damage, and diabetes. Also, the described pharmaceutical composition may be used for preventing cell damage.Type: ApplicationFiled: September 16, 2020Publication date: December 31, 2020Inventors: Che il MOON, Seung Jun YOO, Chang-Hun LEE, So Yeon KIM, Deok Ho LEE
-
Publication number: 20200407411Abstract: The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and formulations comprising the modified RNA. Aspects of the disclosure further relate to preparations and uses of formulations comprising the modified RNA in treating subjects suffering from diseases responsive to VEGF-A therapy.Type: ApplicationFiled: June 6, 2017Publication date: December 31, 2020Applicant: MODERNATX, INCInventors: Leif Karlsson PARINDER, Regina Desirée FRITSCHE DANIELSON, Kenny Mikael HANSSON, Li Ming GAN, Jonathan CLARKE, Ann-Charlotte Eva EGNELL, Kenneth Randall CHIEN
-
Publication number: 20200407412Abstract: A synthetic peptide provided according to the technology disclosed here includes (1) a CMTM4-TM related sequence; and (2) an amino acid sequence that functions as cell membrane permeable peptide. The synthetic peptide has a total number of amino acid residues of 100 or less.Type: ApplicationFiled: June 1, 2020Publication date: December 31, 2020Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida
-
Publication number: 20200407413Abstract: The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.Type: ApplicationFiled: September 11, 2020Publication date: December 31, 2020Applicant: AKSTON BIOSCIENCES CORPORATIONInventors: THOMAS M. LANCASTER, TODD C. ZION
-
Publication number: 20200407414Abstract: The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.Type: ApplicationFiled: September 11, 2020Publication date: December 31, 2020Applicant: AKSTON BIOSCIENCES CORPORATIONInventors: THOMAS M. LANCATER, TODD C. ZION
-
Publication number: 20200407415Abstract: The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and/or pulmonary hypertension.Type: ApplicationFiled: July 9, 2020Publication date: December 31, 2020Inventors: Jasbir S. SEEHRA, Jennifer LACHEY
-
Publication number: 20200407416Abstract: The present disclosure provides antigen-presenting polypeptides, including single-chain antigen-presenting polypeptides and multimeric antigen-presenting polypeptides comprising one or more chemical conjugation sites for incorporation of, for example, epitope containing polypeptides. The present disclosure provides nucleic acids comprising nucleotide sequences encoding antigen-presenting polypeptides comprising one or more chemical conjugation sites, as well as cells genetically modified with the nucleic acids. The single-chain and multimeric antigen-presenting polypeptides and their epitope conjugates are useful for modulating the activity of a T-cell, and accordingly, the present disclosure provides methods of modulating activity of a T-cell in vitro and in vivo as a method of treatment.Type: ApplicationFiled: March 6, 2020Publication date: December 31, 2020Inventors: Ronald D. SEIDEL, III, Rodolfo J. CHAPARRO, John F. Ross
-
Publication number: 20200407417Abstract: A method of recovering a population of extracellular vesicles from a biological sample comprising extracellular vesicles and contaminants is described. In one embodiment, the method comprises: a) removing contaminants from the sample, wherein said contaminants are relatively larger or more dense than the extracellular vesicles; b) contacting the sample of step a) with a plurality of binding compositions, each binding composition having first and/or second moieties capable of binding a recognition motif of the target entities under conditions to allow complexing of the extracellular vesicles with the plurality of binding compositions to form a complexed population of extracellular vesicles, the complexed population of extracellular vesicles having an increased volume and/or higher density in comparison to the extracellular vesicles in individual form; and c) recovering the complexed population of extracellular vesicles.Type: ApplicationFiled: June 26, 2020Publication date: December 31, 2020Inventors: Adil Kassam, Eric Jervis
-
Publication number: 20200407418Abstract: The present invention relates to engineered cells that enable exosome-mediated delivery of therapeutic cargoes, in particular protein therapeutics and RNA therapeutics. The present invention also relates to inventive polynucleotides, polypeptides and pharmaceutical compositions.Type: ApplicationFiled: March 15, 2019Publication date: December 31, 2020Inventor: Joel NORDIN
-
Publication number: 20200407419Abstract: Disclosed herein are extracellular vesicles comprising an immunomodulating component. Also provided are methods for producing the extracellular vesicles and methods for using the extracellular vesicles for treating cancer, GvHD, and autoimmune diseases.Type: ApplicationFiled: July 6, 2020Publication date: December 31, 2020Applicant: Codiak BioSciences, Inc.Inventors: Nuruddeen D. LEWIS, Yu ZHOU, Sriram SATHYANARAYANAN, John KULMAN, Douglas E. WILLIAMS, Leonid A. GAYDUKOV, Ke XU, Shelly MARTIN
-
Publication number: 20200407420Abstract: Provided herein are HER-3, HER-1 and IGF-1R B cell epitopes, peptide mimics, chimeric peptides and multivalent peptides. In some embodiments, the chimeric peptides include one or more HER-3, HER-1 and/or IGF-1R B cell epitopes, a linker, and a T helper cell (Th cell) epitope. Pharmaceutical compositions are also provided that contain one or more HER-3, HER-1 and/or IGF-1R chimeric peptides, and optionally, one or more HER-2 chimeric peptides and/or VEGF peptides. Also included herein are methods of treating a cancer using the HER-3, HER-1 and IGF-1R B cell epitopes, chimeric peptides and multivalent peptides.Type: ApplicationFiled: September 17, 2020Publication date: December 31, 2020Inventor: Pravin T.P. KAUMAYA
-
Publication number: 20200407421Abstract: The present disclosure relates to a method of targeting stems cells, in particular non-apoptotic stem cells, employing a GLA domain, capable of binding surface exposed phosphatidyl serine.Type: ApplicationFiled: September 5, 2018Publication date: December 31, 2020Applicant: GLADIATOR BIOSCIENCES, INC.Inventors: Terry HERMISTON, Maxine BAUZON, Christopher H. CONTAG, Jonathan HARDY, Francis Gerard BLANKENBERG
-
Publication number: 20200407422Abstract: The present disclosure relates to a method of intracellular delivery of a molecule employing a GLA domain to facilitate entry into the cell.Type: ApplicationFiled: September 5, 2018Publication date: December 31, 2020Applicant: GLADIATOR BIOSCIENCES, INC.Inventors: Terry HERMISTON, Maxine BAUZON, Christopher H. CONTAG, Jonathan HARDY, Francis Gerard BLANKENBERG
-
Publication number: 20200407423Abstract: The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.Type: ApplicationFiled: June 15, 2020Publication date: December 31, 2020Inventors: Timothy PABST, Mariko FONSECA, Christopher THOMPSON, Alan HUNTER, Xiangyang WANG, Liu TIE, Yiming LI
-
Publication number: 20200407424Abstract: Novel complexes of peptides from human collagen type II and types of MHC class II associated with rheumatoid arthritis are provided. There is also provided novel therapies and methods for diagnosis of rheumatoid arthritis.Type: ApplicationFiled: September 8, 2020Publication date: December 31, 2020Applicant: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Inventor: Rikard Holmdahl
-
Publication number: 20200407425Abstract: The present invention provides a method of stabilizing a protein. The method includes a step of causing a protein contained in a specimen derived from a living body to coexist with an arylboronic acid. The protein contained in the specimen derived from the living body is at least one type selected from the group consisting of hemoglobin, haptoglobin, and a hemoglobin-haptoglobin complex. According to the present invention, it is possible to stabilize a protein such as a blood protein contained in the specimen derived from a living body. The present invention further provides a stabilizing solution for stabilizing a protein contained in a specimen derived from a living body and a method and a kit for detecting a protein contained in a specimen derived from a living body.Type: ApplicationFiled: February 28, 2019Publication date: December 31, 2020Applicant: EIKEN KAGAKU KABUSHIKI KAISHAInventors: Nozomi SAKAMAKI, Hidenori TAGUCHI, Mitsuru MAKINODAN, Miyu YAMADA
-
Publication number: 20200407426Abstract: Neutralizing antibodies through recombinant protein expression were identified by mining antibody repertoires by high-throughput second generation sequencing. Sequencing across the majority of light and heavy chain variable regions of chicken immunoglobulins was performed at two immunological time points: a non-immune (naive) state and a post-hyperimmunization state. The mRNA was extracted from unsorted and unselected PBMC populations and identification of antigen-specific antibody sequences leveraged the significant disparity of abundance of an individual B cell clone in non-immune and immunized states. Through bioinformatic analysis, candidate amino acid sequences for variable heavy chain and light chains were identified. Recombinant polypeptides with the binding domains having the identified amino acid sequences for variable heavy chain and light chains were expressed and screened using immunoassays to confirm antigen-specificity.Type: ApplicationFiled: December 7, 2016Publication date: December 31, 2020Inventors: Jeff Fagerlund, Bradley M. Mitteness, Connie Phillips